PDGFRB and infantile myofibromatosis: PDGFRB variants of Tier IIC identified in a substrate of infantile myofibromatosis provided indications for imatinib, which afforded significant reduction in pathological foci and the elimination of a life-threatening lesion in the interventricular septum.